Canopy Growth 3Q 2026: Revenue C$99.51M, EPS (C$0.1) — 10-Q Summary

Canopy Growth reported fiscal Q2 revenue of C$99.51M, up 20% YoY, but net loss widened to C$40.69M. Growth in cannabis sales, particularly international and Canadian adult-use, was offset by lower Storz & Bickel sales and higher expenses. Adjusted EBITDA loss narrowed slightly to C$2.9M.

Original reporting
Published Nov 6, 2026, 11:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Canopy Growth 3Q 2026: Revenue C$99.51M, EPS (C$0.1) — 10-Q Summary — source image
Decision brief

The 30-second read

$CGCBearishMed
01

Why it matters

The earnings release provides fresh data on revenue growth versus loss expansion, influencing short‑term price action.

02

Market read

The earnings miss is likely to trigger a near‑term sell‑off in CGC and may affect sentiment across the cannabis sector.

03

What to watch

International market expansion and medical cannabis reimbursement changes may offer upside beyond the headline loss.

Relevance 7/10Novelty 8/10Timing: post‑market today

Background

The article is an AI‑generated summary of Canopy Growth's 10‑Q filing for fiscal Q2 2026.

Company-level read

Ticker impact

$CGCBearishHigh confidence
Context

Canopy Growth reported Q2 revenue of C$99.51M and a widened net loss in its 10‑Q filing.

Expected impact

downward pressure as investors price in the widened loss and higher expenses

Evidence & confidence

The company posted a 20% revenue increase but a 717% loss expansion, which typically triggers a sell‑off.

Market effects

Cannabis sector may see broader pressure as a major player reports a widening loss.

Canadian cannabis market sentiment could soften following the results.

Limited; primarily affects investors focused on North American cannabis stocks.

Counterpoint

Despite the loss, revenue growth and margin improvement in Storz & Bickel could support a longer‑term rebound.

Key entities

  • Canopy Growth Corp

    Canadian cannabis producer listed on the NYSE under CGC.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.